H3 Biomedicine

H3, a subsidiary of Japanese drugmaker Eisai, is developing personalized cancer treatments targeting genomic alterations, including aberrant RNA splicing.

The partnership marries Foundation's genomic knowledgebase with H3's drug discovery engine and computational biology platform.

NEW YORK (GenomeWeb News) – BGI and H3 Biomedicine today announced they will sequence and publish data from next-generation sequencing-based research on pre-clinical cancer models.

This article has been updated to clarify the tools being co-developed by H3 Biomedicine and Sage Bionetworks

NEW YORK (GenomeWeb News) – Cancer biotherapeutics developer H3 Biomedicine said today that it will partner with Sage Bionetworks to develop new software aimed at supporting its efforts to predict human responses to certain drugs.

NEW YORK (GenomeWeb News) – Horizon Discovery and H3 Biomedicine today launched SyntheTx, a technology partnership created to provide novel oncology targets and early-stage drug discovery programs to drug manufacturers.

NEW YORK (GenomeWeb News) – Horizon Discovery and biopharmaceutical firm H3 Biomedicine today announced a collaboration to identify and validate a panel of novel cancer drug targets.

Compendia Bioscience said this week that H3 Biomedicine has signed a three-year licensing agreement to use Compendia's Oncomine tool suite, which includes Oncomine Concepts and Oncomine Power Tools.

"H3 Biomedicine is an independent entity that will have the scientific freedom to choose and follow targets it identifies using genomic insights and modern chemistry, coupled with a disciplined approach to drug discovery and development," an Eisai spokesperson told PGx Reporter.

Pages

A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.

South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.

In Science this week: the synthetic genetic system hachimoji, and more.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.